540
Views
9
CrossRef citations to date
0
Altmetric
Reviews

Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex

, , , , , , , , & show all
Pages 139-147 | Published online: 01 Dec 2009

Bibliography

  • Mehta J, Kelsey S, Chu P, Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997;20:39-43
  • Walsh TJ, Hiemenz JW, Seibel NL, Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96
  • Fleming RV, Kantarjian HM, Husni R, Comparison of amphotericin B lipid complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-20
  • Herbrecht R, Auvrignon A, Andrès E, Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001;20:77-82
  • Wingard JR, White MH, Anaissie E, A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000;31:1155-63
  • Antoniadou A, Dupont B. Lipid formulations of amphotericin B: where are we today? J Mycolog Med 2005;15:230-38
  • Saliba F, Dubont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol 2008;46:97-112
  • Wiley JM, Seibel NL, Walsh TJ. Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections. Pediatr Infect Dis J 2005;24:167-74
  • Furebring M, Oberg G, Sjolin J. Side effects of amphotericin B lipid complex in the Scandinavian population. Bone Marrow Transplant 2000;25:341-3
  • Warnock DW. Trends in the epidemiology of invasive fungal infections. Jpn J Med Mycol 2007;48:1-12
  • Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001;33:1692-6
  • Eccles M, Freemantle N, Mason J. North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. BMJ 1998;316:1232-1235
  • Bowden R, Ckandrasekar P, White M, A double-blind randomized controlled trial of amphotericin B colloidal dispersion versus amphotericin B for the treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-66
  • White M, Bowden R, Sandler E, Randomised double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998;27:296-302
  • Walsh TJ, Finberg RW, Arndt C, Liposomal amphotericin B for empirical therapy in patients with persistant fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-71
  • Rogers DP, Pearson MM, Cleary JD, Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J Antimicrob Chemother 2002;50:811-7
  • Cleary JD, Schwartz M, Rogers DP, Effects of amphotericin B and caspofungin on histamine expression. Pharmacotherapy 2003;23:966-73
  • Conti B, Tabarean I, Andrei C, Cytokines and fever. Front Biosci 2004;1:1433-49
  • Goodwin SD, Cleary JD, Walawander CA, Pretreatment regimens for adverse events related to infusion of Amphotericin B. Clin Infect Dis 1995;20:775-61
  • O'Connor N, Borley A. Prospective audit of the effectiveness of hydrocortisone premedication on drug delivery reactions following amphotericin B lipid complex. Curr Med Res Opin 2009;25:749-54
  • Paterson DL, David K, Mrsic M, Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry. J Antimicrob Chemother 2008;62:1392-400
  • Kuti JL, Kotapati S, Williams P, Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 2004;22:301-10
  • Aguado JM, Lumbreras C, González-Vidal D. Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain. Clin Microbiol Infect 2004;10:785-90
  • Clevenbergh P, Jacobs F, Kentos A. Compassionate use of amphotericin B lipid complex (Abelcet) in life-threatening fungal infections: report of 30 courses. Clin Microbiol Infect 1998;4:192-8
  • Sharkey P, Graybill J, Johnson E, Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996;22:315-21
  • Mattiuzzi GN, Kantarjian H, Faderl S. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004;1:581-9
  • Martino R, Subirá M, Sureda A, Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J Antimicrob Chemother 1999;44:569-72
  • Martino R, Cortés M, Subirá M, Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymphoma 2005;46:1429-435
  • Subirà M, Martino R, Gómez L, Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial. Eur J Haematol 2004;72:342-7
  • Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplantation 2000;14:329-39
  • Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002;49(Suppl 1):37-41
  • Mayer J, Doubek M, Doubek J, Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis 2002;186:379-88
  • Holler B, Omar SA, Farid MD, Effects of fluid and electrolyte management on amphotericin B-induced nephrotoxicity among extremely low birth weight infants. Pediatrics 2004;113:e608-16
  • Echevarria J, Seas C, Cruz M, Oral rehydration solution to prevent nephrotoxicity of amphotericin B. Am J Trop Med Hyg 2006;75:1108-12
  • Miller CB, Waller EK, Klingemann HG, Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients. Bone Marrow Transplant 2004;33:543-8
  • Wong-Beringer A, Jacobs RA, Guglielmo J. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-18
  • Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005;40:S414-21
  • Larkin JA, Montero JA. Efficacy and safety of amphotericin B lipid complex for zygomycosis. Infect Med 2003;20:201-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.